HIF1A and breast carcinoma: Pharmacological inhibition or knockdown of HIF‐1α expression sensitizes resistant breast cancer cells to TAM and other endocrine‐therapy agents,8, 11 which suggests that HIF‐1α may be a promising target for the treatment of TAM‐resistant breast cancer.